<?xml version='1.0' encoding='ISO-8859-1'?>
<xml>
<title>Illinois General Assembly - Bill Status for SB 2788   </title>
<shortdesc>PUB AID-BETA AGONISTS APPROVAL</shortdesc>
<sponsor>
<sponsorhead1>Senate Sponsors</sponsorhead1><sponsors>Sen. Mattie Hunter-Jacqueline Y. Collins, Edward D. Maloney-James T. Meeks-Iris Y. Martinez, Don Harmon-Kimberly A. Lightford, Miguel del Valle, Jeffrey M. Schoenberg and Donne E. Trotter</sponsors>
<sponsorhead2>House Sponsors</sponsorhead2><altsponsors>(Rep. Arthur L. Turner-David E. Miller-Robin Kelly-Elizabeth Coulson, JoAnn D. Osmond, Lovana Jones, Marlow H. Colvin, Karen A. Yarbrough, Karen May, Mary E. Flowers, William Delgado and Cynthia Soto)</altsponsors>
</sponsor>
<lastaction>
<statusdate>1/11/2005</statusdate><chamber>Senate</chamber><action>Session Sine Die</action>
</lastaction>
<synopsis>
<synopsistitle></synopsistitle>
<reference>305 ILCS 5/5-5.12</reference><aliasreference>from Ch. 23, par. 5-5.12</aliasreference><SynopsisText>Amends the Illinois Public Aid Code. Provides that the Department shall not impose requirements for prior approval based on a preferred drug list for any short-acting beta agonists used as rescue therapy in the treatment of life-threatening conditions due to acute bronchospasm in patients with reversible obstructive airway disease that results from asthma, chronic obstructive pulmonary disease or emphysema.</SynopsisText><synopsistitle>Fiscal Note (Department of Public Aid)</synopsistitle>
<SynopsisText>This bill will hamper the Department's ability to enact cost containment measures if prior approval, generic preference and formulary restrictions are exempt for clients diagnosed with a specific disease such as reversible obstructive airway disease. If the Department is unable to require prior approval on any products of this type, the additional cost is estimated to be $2-5 million.</SynopsisText><synopsistitle>Fiscal Note (Department of Public Aid)</synopsistitle>
<SynopsisText>This bill will hamper the Department's ability to enact cost containment measures if prior approval, generic preference and formulary restrictions are exempt for clients diagnosed with a specific disease such as reversible obstructive airway disease. If the Department is unable to require prior approval on any products of this type, the additional cost is estimated to be $2-5 million.</SynopsisText></synopsis>
<actions>
<statusdate>2/5/2004</statusdate><chamber>Senate</chamber><action>Filed with Secretary by Sen. Mattie Hunter</action>
<statusdate>2/5/2004</statusdate><chamber>Senate</chamber><action>First Reading</action>
<statusdate>2/5/2004</statusdate><chamber>Senate</chamber><action>Referred to Rules</action>
<statusdate>2/10/2004</statusdate><chamber>Senate</chamber><action>Added as Chief Co-Sponsor Sen. Jacqueline Y. Collins</action>
<statusdate>2/10/2004</statusdate><chamber>Senate</chamber><action>Added as Co-Sponsor Sen. Edward D. Maloney</action>
<statusdate>2/11/2004</statusdate><chamber>Senate</chamber><action>Added as Chief Co-Sponsor Sen. James T. Meeks</action>
<statusdate>2/11/2004</statusdate><chamber>Senate</chamber><action>Added as Chief Co-Sponsor Sen. Iris Y. Martinez</action>
<statusdate>2/17/2004</statusdate><chamber>Senate</chamber><action>Added as Co-Sponsor Sen. Don Harmon</action>
<statusdate>2/18/2004</statusdate><chamber>Senate</chamber><action>Assigned to State Government</action>
<statusdate>2/18/2004</statusdate><chamber>Senate</chamber><action>Added as Chief Co-Sponsor Sen. Kimberly A. Lightford</action>
<statusdate>2/19/2004</statusdate><chamber>Senate</chamber><action>Added as Co-Sponsor Sen. Miguel del Valle</action>
<statusdate>2/26/2004</statusdate><chamber>Senate</chamber><action>Do Pass State Government;  009-000-000</action>
<statusdate>2/26/2004</statusdate><chamber>Senate</chamber><action>Placed on Calendar Order of 2nd Reading March 2, 2004</action>
<statusdate>3/2/2004</statusdate><chamber>Senate</chamber><action>Fiscal Note Requested by Sen. Dale E. Risinger</action>
<statusdate>3/2/2004</statusdate><chamber>Senate</chamber><action>Added as Co-Sponsor Sen. Jeffrey M. Schoenberg</action>
<statusdate>3/5/2004</statusdate><chamber>Senate</chamber><action>Fiscal Note Filed from the Illinois Department of Public Aid</action>
<statusdate>3/24/2004</statusdate><chamber>Senate</chamber><action>Second Reading</action>
<statusdate>3/24/2004</statusdate><chamber>Senate</chamber><action>Placed on Calendar Order of 3rd Reading March 25, 2004</action>
<statusdate>3/25/2004</statusdate><chamber>Senate</chamber><action>Added as Co-Sponsor Sen. Donne E. Trotter</action>
<statusdate>3/25/2004</statusdate><chamber>Senate</chamber><action>Third Reading - Passed; 055-001-000</action>
<statusdate>3/26/2004</statusdate><chamber>House</chamber><action>Arrived in House</action>
<statusdate>3/26/2004</statusdate><chamber>House</chamber><action>Placed on Calendar Order of First Reading</action>
<statusdate>3/26/2004</statusdate><chamber>House</chamber><action>Chief House Sponsor Rep. Arthur L. Turner</action>
<statusdate>3/26/2004</statusdate><chamber>House</chamber><action>First Reading</action>
<statusdate>3/26/2004</statusdate><chamber>House</chamber><action>Referred to Rules Committee</action>
<statusdate>4/2/2004</statusdate><chamber>House</chamber><action>Assigned to Human Services Committee</action>
<statusdate>4/29/2004</statusdate><chamber>House</chamber><action>Do Pass / Short Debate Human Services Committee;  009-000-000</action>
<statusdate>4/29/2004</statusdate><chamber>House</chamber><action>Placed on Calendar 2nd Reading - Short Debate</action>
<statusdate>5/4/2004</statusdate><chamber>House</chamber><action>Added Alternate Chief Co-Sponsor Rep. David E. Miller</action>
<statusdate>5/4/2004</statusdate><chamber>House</chamber><action>Added Alternate Chief Co-Sponsor Rep. Robin Kelly</action>
<statusdate>5/4/2004</statusdate><chamber>House</chamber><action>Added Alternate Chief Co-Sponsor Rep. Elizabeth Coulson</action>
<statusdate>5/11/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. JoAnn D. Osmond</action>
<statusdate>5/11/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Lovana Jones</action>
<statusdate>5/11/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Marlow H. Colvin</action>
<statusdate>5/11/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Karen A. Yarbrough</action>
<statusdate>5/14/2004</statusdate><chamber>House</chamber><action>Committee/3rd Reading Deadline Extended-Rule 9(b) May 31, 2004</action>
<statusdate>5/19/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Karen May</action>
<statusdate>5/19/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Mary E. Flowers</action>
<statusdate>5/19/2004</statusdate><chamber>House</chamber><action>Fiscal Note Requested by Rep. William B. Black</action>
<statusdate>5/26/2004</statusdate><chamber>House</chamber><action>Fiscal Note Filed</action>
<statusdate>5/27/2004</statusdate><chamber>House</chamber><action>Second Reading - Short Debate</action>
<statusdate>5/27/2004</statusdate><chamber>House</chamber><action>Held on Calendar Order of Second Reading - Short Debate</action>
<statusdate>5/27/2004</statusdate><chamber>House</chamber><action>Placed on Calendar Order of 3rd Reading - Short Debate</action>
<statusdate>5/30/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. William Delgado</action>
<statusdate>5/30/2004</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Cynthia Soto</action>
<statusdate>6/1/2004</statusdate><chamber>House</chamber><action>Rule 19(a) / Re-referred to Rules Committee</action>
<statusdate>1/11/2005</statusdate><chamber>Senate</chamber><action>Session Sine Die</action>
</actions>
</xml>

